Atlas Trials

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Clinical trial NCT03349203 · UNKNOWN

Trial details

NCT number
NCT03349203
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
EGF-R Positive Non-Small Cell Lung Cancer
Start date
2018-10-01
Primary completion
2022-02-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.